Coronary heart disease (CHD) is still the leading cause of mortality in EU. In spite of improved treatments, 10-15% of patients suffer from severe CHD which significantly limits everyday life and predisposes to heart failure. We have developed a novel minimally invasive catheter-based gene therapy for these patients where the treatment is given via coronary veins. The treatment is also applicable to elderly patients who cannot any more be treated with other medical options. Aim of the application is to complete final required regulatory preclinical safety and efficacy study under conditions that are available in cardiology units in order to submit an application to the regulatory authorities to get a permission to move to phase 1 clinical trial. This innovative cardiac gene therapy would then be available to large number of severe CHD and heart failure patients who have no other options left for their treatment. This would be a very significant advancement in clinical cardiology.

2026

2027